Clinical Predictors of Acute Response With Quetiapine in Psychotic Mood Disorders
The DOI matches its Crossref record.
Abstract
BACKGROUND: In controlled studies of patients with schizophrenia, the atypical antipsychotic quetiapine, 300 mg/day, has been shown to be as effective in the treatment of positive and negative symptoms as haloperidol. However, little is known about the efficacy of quetiapine in patients with psychotic mood disorders. The purpose of this study was to assess the efficacy of quetiapine in the treatment of psychotic mood disorders in comparison with nonaffective psychotic disorders and identify clinical factors associated with quetiapine response. METHOD: In a naturalistic setting, by reviewing medical records, we assessed response to quetiapine and factors associated with response to quetiapine in 145 consecutive patients newly treated with the drug at a nonprofit academic psychiatric hospital. These patients had received a discharge diagnosis of bipolar disorder (manic, mixed, or depressive type), major depression with psychotic features, schizophrenia, schizoaffective disorder (bipolar or depressive type), delusional disorder, or psychosis not otherwise specified (NOS) according to DSM-IV criteria. RESULTS: Patients with a diagnosis of bipolar disorder, manic, mixed, or depressed and schizoaffective disorder, bipolar type displayed higher response rates (> 74%) compared with patients with schizophrenia. However, this finding did not achieve statistical significance. A diagnosis of major depression with psychotic features (p = .02) and longer duration of illness (p = .03) were associated with less chance of responding. CONCLUSION: Quetiapine may be a useful alternative or adjunctive treatment for patients with bipolar and schizoaffective disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Calabrese, J. R., Keck, P. E., Macfadden, W., Minkwitz, M., Ketter, T. A., Weisler, R. H., Cutler, A. J., McCoy, R., Wilson, E., Mullen, J., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.7.1351 · Cited by 883
Olanzapine versus placebo in the treatment of acute mania
Tohen, M., Sanger, T. M., McElroy, S. L., Tollefson, G. D., Chengappa, K. N. R., Daniel, D. G., Petty, F., Centorrino, F., Wang, R., Grundy, S. L., et al. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.5.702 · Cited by 585
Tohen, M., Chengappa, K. N. R., Suppes, T., Zarate, C. A., Calabrese, J. R., Bowden, C. L., Sachs, G. S., Kupfer, D. J., Baker, R. W., Risser, R. C., et al. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.1.62 · Cited by 463
Self-citationDELBELLO, M. P., SCHWIERS, M. L., ROSENBERG, H. L., & STRAKOWSKI, S. M. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200210000-00011 · Cited by 443
Bowden, C. L., Grunze, H., Mullen, J., Brecher, M., Paulsson, B., Jones, M., Vågerö, M., & Svensson, K. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0116 · Cited by 376
Tohen, M., Chengappa, K. N. R., Suppes, T., Baker, R. W., Zarate, C. A., Bowden, C. L., Sachs, G. S., Kupfer, D. J., Ghaemi, S. N., Feldman, P. D., et al. (2004) · British Journal of Psychiatry · doi:10.1192/bjp.184.4.337 · Cited by 326
Self-citationSachs, G., Chengappa, K., Suppes, T., Mullen, J., Brecher, M., Devine, N., & Sweitzer, D. (2004) · Bipolar Disorders · doi:10.1111/j.1399-5618.2004.00115.x · Cited by 262
Volkow, N. D., Wang, G.-J., Tomasi, D., Kollins, S. H., Wigal, T. L., Newcorn, J. H., Telang, F. W., Fowler, J. S., Logan, J., Wong, C. T., et al. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.4461-11.2012 · Cited by 237
Tremblay, L. K., Naranjo, C. A., Cardenas, L., Herrmann, N., & Busto, U. E. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.5.409 · Cited by 229
Grunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Azorin, J.-M., Yatham, L., Mosolov, S., Möller, H.-J., Kasper, S., et al. (2018) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1384850 · Cited by 187
“A retrospective study of patients with bipolar disorder and other bipolar spectrum disorders, reported that the proportion of mixed patients responding to quetiapine was 77% (Zarate et al. 2000).”
BackgroundCheniaux, E., Landeira-Fernandez, J., Lessa Telles, L., Lessa, J. L. M., Dias, A., Duncan, T., & Versiani, M. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2007.07.009 · Cited by 170
Clinical Predictors of Ketamine Response in Treatment-Resistant Major Depression
Niciu, M. J., Luckenbaugh, D. A., Ionescu, D. F., Guevara, S., Machado-Vieira, R., Richards, E. M., Brutsche, N. E., Nolan, N. M., & Zarate, C. A. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08698 · Cited by 165
Self-citationJacobsen, L. K., Picciotto, M. R., Heath, C. J., Frost, S. J., Tsou, K. A., Dwan, R. A., Jackowski, M. P., Constable, R. T., & Mencl, W. E. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2402-07.2007 · Cited by 147
Psychiatric profile and attention deficits in postural tachycardia syndrome
Raj, V, Haman, K. L., Raj, S. R., Byrne, D., Blakely, R. D., Biaggioni, I., Robertson, D., & Shelton, R. C. (2009) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.144360 · Cited by 131
Quetiapine in bipolar disorder and cocaine dependence
Brown, E. S., Nejtek, V. A., Perantie, D. C., & Bobadilla, L. (2002) · Bipolar Disorders · doi:10.1034/j.1399-5618.2002.02229.x · Cited by 122
Standardisation framework for the Maudsley staging method for treatment resistance in depression
Fekadu, A., Donocik, J. G., & Cleare, A. J. (2018) · BMC Psychiatry · doi:10.1186/s12888-018-1679-x · Cited by 106
“Studies have consistently demonstrated that the longer the duration of illness, the poorer the response to treatment in the acute phase of [81, 82, 92, 93] or augmentation [94] and predicted shorter relapse free survival [79, 95].”
BackgroundThe Cost of Relapse for Patients with a Manic/Mixed Episode of Bipolar Disorder in the EMBLEM Study
Hong, J., Reed, C., Novick, D., Haro, J. M., Windmeijer, F., & Knapp, M. (2010) · PharmacoEconomics · doi:10.2165/11535200-000000000-00000 · Cited by 26
“Having more severe bipolar symptoms at baseline is often suggested as predictive of poorer treatment outcome,([42,43]) and thus probably led to more resource use over the follow-up period, even if the patients did not meet the definition of relapse.”
BackgroundEffectiveness of intravenous ketamine in mood disorder patients with a history of neurostimulation
Rodrigues, N. B., Siegel, A., Lipsitz, O., Cha, D. S., Gill, H., Nasri, F., Simonson, K., Shekotikhina, M., Lee, Y., Subramaniapillai, M., et al. (2022) · CNS Spectrums · doi:10.1017/s1092852920002187 · Cited by 17
“outcomes.(2,7,8) Moreover, without maintenance treatment, relapses approximate 50%, even following successful ECT treatment.”
Background
Metadata
- Authors
- Zarate, C. A., Rothschild, A., Fletcher, K. E., Madrid, A., & Zapatel, J.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2000-03-15
- Volume
- 61
- Issue
- 3
- Pages
- 185-189
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2070765534
- Cited by
- 124
- References
- 0
- FWCI
- 10.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.